Cabaletta Bio Inc (CABA)

May 25, 2026

Cabaletta Bio(CABA) Stock Options Chain | Quotes & News - Moomoo

May 25, 2026

May 24, 2026

CABA stock on track for best day in 6 months after positive early results from cell therapy trial - MSN

May 24, 2026

May 22, 2026

CABA Stock Price, Quote & Chart | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill

May 22, 2026

May 22, 2026

Cabaletta Bio (CABA) upgraded to buy: Here's why - MSN

May 22, 2026

May 21, 2026

Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN

May 21, 2026

May 20, 2026

Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

May 20, 2026

May 18, 2026

Cabaletta Bio (CABA) Upgraded to Buy: Here's Why - sharewise.com

May 18, 2026

May 15, 2026

Guggenheim Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo

May 15, 2026

May 15, 2026

Cabaletta Bio Inc (CABA) Stock Price, Quote, News & History - Benzinga

May 15, 2026

May 15, 2026

Cormorant Funds disclose 10.5M-share position in Cabaletta Bio (CABA) - Stock Titan

May 15, 2026

May 15, 2026

CABA Maintains Rating by Wells Fargo -- Price Target Raised to $4.00 - GuruFocus

May 15, 2026

May 15, 2026

A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $16 to $16 - Moomoo

May 15, 2026

May 15, 2026

Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Cuts Target Price to $3.61 - Moomoo

May 15, 2026

May 15, 2026

Cabaletta Bio Is Maintained at Equal-Weight by Wells Fargo - Moomoo

May 15, 2026

May 15, 2026

H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo

May 15, 2026

May 15, 2026

Key facts: Cabaletta Q1 $0.39 Adj Loss, $43.52M Net Loss; ASGCT Data - TradingView

May 15, 2026

May 14, 2026

CABA Shows Promising Results in New Clinical Data - GuruFocus

May 14, 2026

May 14, 2026

CABA: Cabaletta Bio Signs Major Supply Agreement and Reports Pro - GuruFocus

May 14, 2026

May 14, 2026

Cabaletta Bio 2026 Q1 10-Q Filing: Financials, Risk Factors, and Forward-Looking Statements - Minichart

May 14, 2026

May 14, 2026

Cabaletta Bio Unveils Promising Preconditioning-Free Rese-cel CAR-T Data and Automated Manufacturing Advances at ASGCT 2026 Annual Meeting - Minichart

May 14, 2026

May 14, 2026

Cabaletta Bio Reports Promising 2026 Q1 Results: Rese-cel CAR-T Therapy Advances, New Data & $150M Financing Highlighted - Minichart

May 14, 2026

May 14, 2026

Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune (CABA) - Seeking Alpha

May 14, 2026

May 14, 2026

Cabaletta Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2026

May 14, 2026

Is Cabaletta Bio (CABA) Fairly Valued After Q1 2026? EPS -$0.39 - GuruFocus

May 14, 2026

May 14, 2026

Cabaletta Bio presents data on preconditioning-free rese-cel - Investing.com UK

May 14, 2026

May 14, 2026

Cabaletta Bio presents data on preconditioning-free rese-cel By Investing.com - Investing.com Nigeria

May 14, 2026

May 14, 2026

Cabaletta Bio Reports Encouraging RESET-PV Trial Data - TipRanks

May 14, 2026

May 14, 2026

Cabaletta Bio (NASDAQ: CABA) details Q1 loss and $150M financing - Stock Titan

May 14, 2026

May 14, 2026

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times

May 14, 2026

May 14, 2026

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting - The Manila Times

May 14, 2026

May 14, 2026

Cabaletta Bio (NASDAQ: CABA) warns on going concern despite $141M cash raise - Stock Titan

May 14, 2026

May 14, 2026

Cabaletta Bio, Inc. 1Q 2026: Net loss $(43.5M), EPS $(0.39) — 10-Q Summary - TradingView

May 14, 2026

May 14, 2026

Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 14, 2026

May 14, 2026

Press Release: Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo

May 14, 2026

May 14, 2026

Cabaletta Bio (NASDAQ: CABA) unveils new rese-cel autoimmune and PC-free data - Stock Titan

May 14, 2026

May 14, 2026

Early autoimmune trial: 2 of 4 patients drug-free 6 months after cell therapy - Stock Titan

May 14, 2026

May 13, 2026

U.S. Earnings Preview: Before Market Open May 13 - Moomoo

May 13, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

May 08, 2026

Cabaletta Bio (CABA) Eps Diluted (TTM) - Zacks Investment Research

May 08, 2026

May 08, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 08, 2026

May 07, 2026

Cabaletta Bio (CABA) Is Up 34.2% After Early RESET-PV Data And US$150M Equity Raise - simplywall.st

May 07, 2026

May 06, 2026

Number of shareholders of Cabaletta Bio, Inc. – NASDAQ:CABA - TradingView

May 06, 2026

May 06, 2026

Number of shareholders of Cabaletta Bio, Inc. – BMV:CABA - TradingView

May 06, 2026